Allbirds (BIRD) Q2 Revenue Falls 23%

Allbirds (BIRD) reported mixed Q2 2025 results, exceeding GAAP revenue and EPS estimates but experiencing a significant 23.1% year-over-year revenue decline to $39.7 million and a sharp gross margin contraction to 40.7%. These pressures stemmed from strategic shifts, including a transition to international distributors, store closures, and increased promotional activity. Consequently, management lowered its full-year 2025 revenue guidance to $165-$180 million, reflecting a slower anticipated sales recovery. While the company improved cost control, investors will closely monitor the impact of new product launches and the expected rebound in gross margins in H2 2025 for signs of sustainable top-line growth.

Analysis

Allbirds (BIRD) reported mixed Q2 2025 results, surpassing analyst expectations on GAAP revenue and EPS but revealing significant underlying business pressures. While net revenue of $39.7 million and a loss per share of $(1.92) beat forecasts, the top line contracted sharply by 23.1% year-over-year. This decline was driven by a strategic pivot involving store closures and a shift to a lower-margin international distributor model, which impacted U.S. and international revenues by -21.8% and -26.2% respectively. Profitability eroded substantially, with gross margin falling nearly 10 percentage points to 40.7% from 50.5% in the prior year, a direct result of increased promotions, inventory adjustments, and higher costs. Consequently, management lowered its full-year 2025 revenue guidance to a range of $165–$180 million, down from $175–$195 million, signaling a slower recovery. Although the company demonstrated improved cost control, with SG&A expenses decreasing, the investment outlook is now heavily dependent on a successful second-half execution, including the launch of new higher-margin products and a return to growth in Q4.

Key Decisions for Investors

• Despite the earnings beat, investors should focus on the severe 23.1% revenue contraction and the sharp gross margin decline to 40.7%, as these metrics signal deep operational challenges underlying the company's strategic transformation.
• The lowered full-year revenue guidance to $165-$180 million warrants a re-evaluation of valuation models, reflecting the significant execution risk and slower-than-expected sales recovery.
• The investment thesis now hinges on a successful second-half 2025 turnaround; therefore, closely monitor gross margin recovery, traction from new product launches, and the company's ability to achieve its forecasted return to growth in Q4.
• Pay close attention to the company's liquidity, as the $33.1 million in cash will be critical to sustaining operations through the ongoing transformation amid projected full-year adjusted EBITDA losses of $55-$65 million.